Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842751 | 0.86 | KDM4E (0.51) | CYP2C19RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL18134649 | 0.85 | KDM4E (0.44) | CYP3A4CYP2C19RAB9ANPC1KDM4E | |
| SCHEMBL19139275 | 0.85 | CYP3A4 (0.43) | CYP3A4CYP2C19RAB9ANPC1KDM4E | |
| SCHEMBL8573566 | 0.80 | RAB9A (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL23122799 | 0.79 | RAB9A (0.47) | CYP3A4CYP2C19RAB9ANPC1KDM4E | |
| SCHEMBL1406834 | 0.79 | NPC1 (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL4701434 | 0.79 | RAB9A (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1458129 | 0.79 | ALDH1A1 (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL10729743 | 0.78 | RAB9A (0.46) | CYP3A4CYP2C19RAB9ANPC1KDM4E | |
| SCHEMBL8986609 | 0.78 | RAB9A (0.48) | CYP3A4CYP2C19RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708273-B2 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-8557832-B2 | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | CYP3A4 419/4885CYP2C19 228/4885RAB9A 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.